Prescient Therapeutics (ASX:PTX) Launches SPP to Boost Cancer Therapy Trials | All Ordinaries

Highlights

• Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development

• Proceeds to fund Phase 2 trials in treating relapsed cutaneous T-cell lymphoma

• PTX-100 holds FDA Orphan Drug and Fast Track status for advanced cancer therapy

Prescient Therapeutics Ltd (ASX:PTX), a biotechnology company listed on the All Ordinaries, has initiated a Share Purchase Plan (SPP) aimed at securing funds for the next phase of clinical development for its lead anti-cancer compound, PTX-100. The offer is available to eligible shareholders based on the record date and will be detailed further in an official SPP Offer Booklet.

The company's strategic direction remains focused on targeted therapies for cancer, with PTX-100 forming a key part of its pipeline. The funds raised through the SPP are earmarked for advancing its regulatory and clinical agenda.

PTX-100 Progresses Through Mid-Stage Clinical Trials

PTX-100 is currently in Phase 2A clinical development for patients diagnosed with relapsed or refractory cutaneous T-cell lymphoma (CTCL). This therapy operates as an inhibitor of geranylgeranyl transferase-1 (GGT-1), disrupting key cellular processes essential for cancer progression.

This compound has been granted Orphan Drug and Fast Track designations by the US Food and Drug Administration (FDA), underscoring its therapeutic relevance in the oncology landscape. These regulatory endorsements may provide avenues for expedited review and development.

The Phase 2A trial recently began with the dosing of the first patient, building on the encouraging safety and efficacy outcomes observed in earlier Phase 1B studies. PTX-100 specifically targets the Ras signaling pathway, widely implicated across various cancers.

Broader Oncology Platform in Focus

Beyond PTX-100, Prescient’s clinical strategy encompasses several platforms designed to optimise cell-based cancer therapies. These include:

• CellPryme-M and CellPryme-A: Technologies aimed at enhancing T-cell therapy effectiveness by improving the tumour microenvironment and cellular function.

• OmniCAR: A universal immune receptor platform offering modular design for CAR-T therapies, currently under preclinical evaluation.

Participation Process and SPP Administration

Eligible shareholders may submit applications for the SPP through BPAY or by returning a completed Application Form with payment by the scheduled deadline. Details regarding pricing, eligibility, and full terms of participation are outlined in the SPP Offer Booklet, available through Prescient’s investor portal.

The SPP is being managed by Reach Markets Pty Ltd, which will provide administrative support and guidance throughout the offer period.